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There are significant limitations to current widely prescribed 
antidepressant treatments. These include a significant delay in 
the onset of therapeutic action (weeks to months) and approxi-
mately one-third of patients with major depressive disorder 
(MDD) failing to demonstrate an adequate response (Al-Harbi, 
2012). For individuals with depression, particularly if suffering 
from suicidal ideation, these time lags and resistance to standard 
treatments can be extremely harmful (Hantouche et al., 2010).
Increasing evidence has revealed that the dissociative anaes-
thetic ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) 
receptor antagonist, has the potential to overcome such limitations, 
demonstrating rapid antidepressant and anti-suicidal effects, even in 
treatment-resistant patients (Coyle and Laws, 2015; Kishimoto 
et al., 2016). It has been proposed that ketamine’s antidepressant 
effects are primarily mediated through NMDA receptor antago-
nism, resulting in disinhibition of pyramidal cells and an acute cor-
tical glutamate surge, with downstream effects on synaptogenesis 
and neuroplastic pathways (Lener et al., 2017). However, the pre-
cise molecular and cellular processes underlying ketamine’s antide-
pressant effects are still not clear and evidence suggests that 
mechanisms other than NMDA receptor inhibition play a more cru-
cial role in the antidepressant effects of ketamine, its component 
enantiomers and metabolites (Jelen et al., 2018; Zanos et al., 2016).
In this review, we summarise findings on the antidepressant 
effects of ketamine and its enantiomers. We then discuss underly-
ing therapeutic mechanisms, exploring the case that ketamine’s 
enantiomers and metabolites may produce complementary anti-
depressant effects via distinct mechanisms, before considering 
future directions of enquiry.
Ketamine enantiomers and 
metabolites
Ketamine is a racemic mixture that consists of equal amounts of 
two enantiomers, (S)-ketamine and (R)-ketamine (or esketamine 
and arketamine) (Figure 1). (S)-ketamine has a three to fourfold 
greater binding affinity for the NMDA receptor than (R)-ketamine 
(Ki = 0.30 μM and Ki = 1.4 μM respectively) (Ebert et al., 
1997). In humans, (S)-ketamine is more potent than (R)-ketamine 
both as an anaesthetic and as an analgesic, which is putatively 
explained by its higher affinity for the NMDA receptor (White 
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et al., 1980, 1985). It was argued that because of its increased 
potency, lower doses of (S)-ketamine could be used in anaesthe-
sia/analgesia with faster recovery times and therefore potentially 
some diminution in dissociative and psychotomimetic side 
effects (Kohrs and Durieux, 1998). However, direct comparative 
studies of (S)- and (R)-ketamine have suggested otherwise. In 
one study, higher rates of psychotomimetic side effects were seen 
in an (S)-ketamine treated group, despite the dose of (S)-ketamine 
being lower than (R)-ketamine (0.45 mg/kg and 1.8 mg/kg 
respectively) (Mathisen et al., 1995). Furthermore, a healthy vol-
unteer study from Vollenweider et al. (1997) found that although 
(S)-ketamine administration produced acute psychosis-like reac-
tions (ego-dissolution, illusions and hallucinations, thought dis-
orders, paranoid ideations), in the same individuals (R)-ketamine 
did not produce any psychotic symptoms but instead led to a state 
of relaxation and a feeling of wellbeing.
(S)-ketamine and (R)-ketamine both undergo extensive 
metabolism by cytochrome P450 enzymes to corresponding 
forms of norketamine, dehydronorketamine (DHNK), hydrox-
yketamine (HK) and hydroxynorketamines (HNKs) (Zanos et al., 
2018; Zarate et al., 2012a) (Figure 2). (S)-ketamine or 
(R)-ketamine is first demethylated by either CYP3A4 or CYP2B6 
to (S)-norketamine or (R)-norketamine. (S)-norketamine or 
(R)-norketamine are subsequently metabolised to (S)-DHNK or 
(R)-DHNK or HNKs. Hydroxylation of (S)-norketamine or 
(R)-norketamine by CYP2A6 at the six position results in 
(2S,6S)-HNK and (2R,6R)-HNK respectively, which are the 
major HNK metabolites found in plasma following ketamine 
infusion (Moaddel et al., 2010; Zarate et al., 2012a). CYP2A6 
can also directly hydroxylate (S)-ketamine or (R)-ketamine to 
form (2S,6S)-HK and (2R,6R)-HK, which are further trans-
formed to (2S,6S)-HNK or (2R,6R)-HNK (Desta et al., 2012). Of 
these metabolites, (2R,6R)-HNK and (S)-norketamine have 
attracted particular interest as candidate antidepressants in their 
own right (Yang et al., 2018a; Zanos et al., 2016).
Ketamine as an antidepressant
(R,S)-ketamine: In the first double-blind, placebo-controlled 
study of racemic ketamine in MDD, it was demonstrated that a 
Figure 1. Chemical structure of ketamine enantiomers. (S)-ketamine and (R)-ketamine are a pair of stereoisomers that are non-superimposable 
mirror images of each other. An example of familiar objects that are related in such a way are the left and right hand.
Figure 2. Major metabolites of (S)-ketamine and (R)-ketamine. (S)-ketamine or (R)-ketamine are initially metabolised to (S)-norketamine or (R)-
norketamine via CYP3A4 or CYP2B6. (S)-norketamine or (R)-norketamine are further metabolised to (S)-dehydronorketamine (DHNK) or (R)-DHNK. 
(S)-norketamine or (R)-norketamine are metabolised to (2S,6S)-hydroxynorketamine (HNK) or (2R,6R)-HNK via CYP2A6. (S)-ketamine or (R)-
ketamine may also be metabolised to (2S,6S)-HK or (2R,6R)-hydroxyketamine (HK) via CYP2A6 before transformation to (2S,6S)-HNK or (2R,6R)-
HNK. Metabolites identified as candidate antidepressants are highlighted in dashed boxes.
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single sub-anaesthetic intravenous (IV) infusion (0.5 mg/kg over 
40 mins) resulted in rapid antidepressant effects, within hours of 
administration (Berman et al., 2000). A number of subsequent 
studies have also demonstrated the rapid-acting antidepressant 
effects of ketamine in treatment-resistant unipolar and bipolar 
depression (Price et al., 2009; Zarate et al., 2006, 2012b). 
Findings have been reviewed in several meta-analyses, which 
report robust antidepressant and anti-suicidal effects, lasting up 
to 1 week, in treatment-resistant MDD and bipolar depression 
(Kishimoto et al., 2016; Wilkinson et al., 2018), with acute dis-
sociative symptoms being the most commonly reported side 
effect (Kishimoto et al., 2016).
Unfortunately, the antidepressant effect of a single dose of 
ketamine is not generally sustained beyond 1 week (Kishimoto 
et al., 2016). In the first randomised controlled trial (RCT) of 
repeated ketamine administration, it was shown that twice- or 
thrice-weekly administration of IV ketamine (0.5 mg/kg over 
40 mins) was sufficient to maintain antidepressant efficacy over 
15 days in individuals with treatment-resistant depression (TRD) 
(Singh et al., 2016b). Similar findings have also been reported in 
open-label repeated infusion studies (Rasmussen et al., 2013; 
Shiroma et al., 2014; Zheng et al., 2018). In contrast, a recent 
RCT investigating the effects of six ketamine infusions (0.5 mg/
kg over 45 mins) or saline placebo over 3 weeks in severe TRD 
with current, chronic suicidal ideation failed to demonstrate a 
significant difference in depression severity or suicidality at the 
3 week endpoint (Ionescu et al., 2019). However, this study was 
limited by a small sample size (out of 26 randomised patients, 
n=13 per group, only 14 completed the entire study) and therefore 
may have been underpowered to detect a true difference between 
treatment groups. In addition, all patients were maintained on 
their medication regimes throughout the infusion phase and the 
impact that concomitant medications may have had on keta-
mine’s effects cannot be ruled out.
Although there are specialist centres around the world and an 
increasing number of ketamine clinics in the United States offer-
ing ketamine infusions for depression (Ketamine-Clinics-
Directory, 2020), the use of repeated infusions may not be the 
most practical due to the resources required. Other routes of 
administration (oral, sublingual, intranasal, intramuscular or sub-
cutaneous) could prove to be simpler and more feasible alterna-
tives for repeated administration but few studies have evaluated 
these options (Andrade, 2017).
(S)-ketamine: As NMDA receptor antagonism was under-
stood to play a key role in ketamine’s antidepressant mechanism, 
(S)-ketamine was investigated as a novel antidepressant candi-
date by Janssen Research & Development due to its higher affin-
ity for the NMDA receptor. In a first proof-of-concept trial, IV 
(S)-ketamine at doses of 0.2 mg/kg and 0.4 mg/kg led to rapid and 
robust antidepressant effects in individuals with TRD (Singh 
et al., 2016a). Side effects included headache, nausea and disso-
ciation. It was suggested that as improvements in depressive 
symptoms were not significantly different between the two tested 
doses that a lower dose of (S)-ketamine may allow for better tol-
erability while maintaining efficacy (Singh et al., 2016a).
A fixed-dose (S)-ketamine nasal spray has subsequently been 
developed and tested in TRD. A number of Phase II and III trials 
have shown that intranasal (S)-ketamine plus an existing or newly 
initiated oral antidepressant outperforms placebo plus an oral anti-
depressant for individuals with TRD (Canuso et al., 2018; Daly 
et al., 2018, 2019; Popova et al., 2019), although others failed to 
demonstrate positive results (Fedgchin et al., 2019; Ochs-Ross 
et al., 2020). In a large discontinuation study, 297 individuals with 
TRD who met response or remission criteria following 16 weeks of 
treatment with intranasal (S)-ketamine (56 mg or 84 mg twice 
weekly) plus an oral antidepressant were entered into a randomised 
withdrawal phase (to continue with (S)-ketamine or switch to pla-
cebo) (Daly et al., 2019). Those randomised to continue treatment 
with intermittently administered (S)-ketamine nasal spray plus an 
oral antidepressant had a significantly delayed time to relapse 
compared to those treated with placebo nasal spray and oral antide-
pressants. A subsequent open-label study has examined the long-
term safety of (S)-ketamine nasal spray plus a new oral 
antidepressant in patients with TRD (Wajs et al., 2020). Common 
treatment-emergent adverse events included dizziness, dissocia-
tion, nausea and headache, which mostly occurred on dosing days, 
were mild to moderate in severity and resolved on the same day. 
Longitudinal analysis showed dissociative symptoms declined 
over subsequent administrations and cognitive performance was 
generally found to either improve or remained stable compared 
with baseline. Similar long-term maintenance or safety evidence of 
this level are not available for (R,S)- or (R)-ketamine at this time.
Considering the available evidence, the United States Food 
and Drug Administration and European Medicines Agency have 
approved the (S)-ketamine nasal spray, SpravatoTM, for adults 
with TRD in combination with an oral antidepressant. However, 
some questions remain regarding uncertainty of efficacy, safety, 
potential for abuse and need for careful monitoring, which cur-
rently limit wider use (Kryst et al., 2020; Turner, 2019).
(R)-ketamine: Preclinical findings have suggested (R)- 
ketamine has the potential for more potent and longer-lasting 
antidepressant effects than both ketamine and (S)-ketamine and 
it appears to have less behavioural side-effects and abuse liabil-
ity (Chang et al., 2019; Fukumoto et al., 2017; Yang et al., 2015; 
Zanos et al., 2016). Given initial findings from Vollenweider 
et al. (1997) in healthy subjects, where (R)-ketamine did not 
produce psychosis-like symptoms as seen with (S)-ketamine, 
but instead feelings of relaxation and wellbeing, researchers 
have now begun to explore the antidepressant potential of 
(R)-ketamine in humans (Leal et al., 2020).
In the first open-label pilot study of (R)-ketamine, seven sub-
jects with TRD received a single IV infusion of (R)-ketamine at a 
dose of 0.5 mg/kg over 40 mins (Leal et al., 2020). Mean 
Montgomery-Åsberg Depression Rating Scale scores dropped sig-
nificantly from 30.7 at baseline to 10.4 at day 1 after the infusion, 
with 71% of subjects showing an antidepressant response at day 1 
and 57% at day 7. Interestingly, dissociation was nearly absent 
with minimal haemodynamic effects. However, it should be noted 
that five out of the seven patients in this study were taking antipsy-
chotic medications (quetiapine (three), risperidone (one), aripipra-
zole (one)) that might have resulted in lower blood pressure or less 
dissociation. Naturally, the results of this small open-label study 
must be interpreted with caution. A clinical trial is underway by 
Perception Neuroscience to further investigate safety and tolerabil-
ity of differing doses of (R)-ketamine in healthy volunteers before 
exploring its potential in depression (Universal Trial Number: 
U1111-1241-1005). In addition, a large trial comparing the effi-
cacy and safety of (R)-ketamine with (S)-ketamine and (R,S)-
ketamine in TRD is already underway in China 
(ChiCTR1800015879).
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Mechanistic considerations
NMDA receptor antagonism and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor activation
It has been widely acknowledged that the rapid antidepressant 
effects of ketamine are mediated through blockade of NMDA 
receptors located on γ-aminobutyric acid (GABA)-ergic inhibi-
tory interneurons (Krystal et al., 2019a). This in turn leads to a 
disinhibition of pyramidal cells and an acute cortical glutamate 
surge. Subsequent activation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors appears to play a key 
role in the antidepressant effects as demonstrated by preclinical 
work that has shown pre-treatment with an AMPA receptor 
antagonist blocks the antidepressant effects of ketamine and its 
enantiomers in rodent models (Autry et al., 2011; Maeng et al., 
2008; Yang et al., 2015).
It has been reported that the metabolism of (R,S)-ketamine to 
HNK, is required for ketamine’s antidepressant-like effects in 
rodents (Zanos et al., 2016). Administration of the (R)-enantiomer 
(2R,6R)-HNK was associated with greater and longer-lasting 
antidepressant effects than (2S,6S)-HNK and MK-801, a more 
potent NMDA receptor antagonist. Importantly, (2R,6R)-HNK 
lacked ketamine-related side-effects and abuse potential in this 
model. Furthermore, the antidepressant effects were independent 
of any action on NMDA receptors but instead required AMPA 
receptor activation (Zanos et al., 2016). Subsequent work has 
also suggested an important role of presynaptic group II metabo-
tropic glutamate (mGlu2) autoreceptor inhibition in the antide-
pressant actions of (2R,6R)-HNK (Zanos et al., 2019). Although 
findings with regards to antidepressant-like effects of (2R,6R)-
HNK in rodents have been replicated by other independent labo-
ratories (Fukumoto et al., 2019; Pham et al., 2018), other studies 
from one laboratory were unable to reproduce this and instead 
suggest unmetabolised (R)-ketamine itself may be responsible 
for the antidepressant actions (Shirayama and Hashimoto, 2018; 
Yamaguchi et al., 2018; Yang et al., 2017a). Clinical trials have 
not yet examined the utility of (2R,6R)-HNK as a rapid-acting 
antidepressant. However, clinical studies investigating ketamine 
metabolite plasma levels as biomarkers have found that higher 
(2R,6R)-HNK levels were associated with less improvement in 
depressive symptoms (Farmer et al., 2020; Grunebaum et al., 
2019), which is counterintuitive considering preclinical findings. 
Regardless, (2R,6R)-HNK, with its potential to modulate mGlu2 
and AMPA receptor function, remains a promising candidate 
antidepressant and work to validate this compound for clinical 
use is ongoing at the United States National Institute for Mental 
Health (Kraus et al., 2019).
(S)-ketamine is primarily metabolised to (S)-norketamine 
and it has been shown in an animal model that although the anti-
depressant actions of the metabolite are similarly potent to the 
parent compound, (S)-norketamine appeared to lack the associ-
ated side effects (Yang et al., 2018a). Importantly, the findings 
of this study suggest that AMPA receptor activation is not neces-
sary for the antidepressant actions of (S)-nortketamine as AMPA 
receptor antagonists did not block its antidepressant effects, 
instead highlighting a role for brain-derived neurotrophic factor 
(BDNF), tropomyosin kinase B (TrkB) and mechanistic target of 
rapamycin complex (mTORC) signalling (Yang et al., 2018a). 
There is, however, some recent clinical evidence that found no 
relationship between norketamine concentration (neither 
(S)-norketamine nor (R)-norketamine) and antidepressant 
response, following administration of (R,S)-ketamine to indi-
viduals with TRD (Farmer et al., 2020).
GABAergic interneuron inhibition
The preferential action of (R,S)-ketamine at GABAergic 
interneurons is supported by findings that the NMDA receptor 
antagonist MK-801 initially inhibits the firing of fast-spiking 
GABAergic interneurons and, at a delayed rate, increases the fir-
ing rate of pyramidal neurons (Homayoun and Moghaddam, 
2007). Widman et al. (2018) have since demonstrated that perfu-
sion of hippocampal rat brain slices with (R,S)-ketamine 
enhances the excitability of pyramidal cells indirectly by reduc-
ing synaptic GABAergic inhibition, thus causing disinhibition. A 
recent study found that knockdown of a key NMDA receptor 
subunit, GluN2B, on GABAergic interneurons resulted in a sig-
nificant increase (disinhibition) of spontaneous excitatory post-
synaptic currents on layer V pyramidal cells in mouse brain slices 
(Gerhard et al., 2020). Moreover, knockdown of GluN2B on 
GABAergic interneurons but not pyramidal cells of the medial 
prefrontal cortex (mPFC) had antidepressant-like effects and 
occluded or blocked the antidepressant behavioural effects of 
(R,S)-ketamine. Further supporting this disinhibition hypothesis, 
administration of negative allosteric modulators of GABAA 
receptors (GABA-NAMs) exert rapid antidepressant actions sim-
ilar to (R,S)-ketamine in animal models (Fischell et al., 2015; 
Zanos et al., 2017), likely through disinhibition of excitatory glu-
tamatergic neurotransmission (Towers et al., 2004). Although 
GABAergic interneuron inhibition via NMDA receptors appears 
to serve as an important initial target of (R,S)-ketamine, further 
work is needed to determine if this mechanism is as relevant for 
each of ketamine’s enantiomers and metabolites.
BDNF-TrkB signalling
BDNF and its receptor TrkB have been consistently implicated in 
the aetiology of depression and mechanism of action of current anti-
depressants (Duman and Monteggia, 2006; Dwivedi, 2009; 
Hashimoto et al., 2004). BDNF serves a key a role in processes 
including neuronal maturation, synapse formation and synaptic plas-
ticity (Park and Poo, 2013). Findings from preclinical work suggest 
BDNF-TrkB signalling in the hippocampus and prefrontal cortex to 
be a critical component of antidepressant response to conventional 
antidepressants (Adachi et al., 2008; Rantamaki et al., 2007; Schmidt 
and Duman, 2010). The rapid antidepressant-like effects of (R,S)-
ketamine have been shown in one preclinical study to depend on the 
rapid synthesis of BDNF (Autry et al., 2011). In this study, (R,S)-
ketamine was shown to rapidly increase TrkB phosphorylation, an 
indicator of TrkB activation, in the hippocampus, suggesting BDNF-
TrkB signalling in this brain region is also involved in the antide-
pressant response to ketamine. This is in agreement with previous 
work showing the acute antidepressant effects of (R,S)-ketamine 
administration are associated with increased BDNF protein levels in 
the hippocampus (Garcia et al., 2008).
In the study by Autry et al. (2011), the ketamine-mediated sup-
pression of resting NMDA receptor activity was also shown to 
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deactivate eukaryotic elongation factor 2 (eEF2) kinase, resulting 
in reduced eEF2 phosphorylation and augmentation of BDNF syn-
thesis. Subsequent findings confirmed the importance of this sig-
nalling pathway in the antidepressant response to ketamine as 
eEF2 kinase knockout mice, administered an acute low dose of 
(R,S)-ketamine did not show an antidepressant response or an 
increase in BDNF protein expression in the hippocampus 
(Nosyreva et al., 2013). In addition to the hippocampus, BDNF in 
the mPFC may also be an important site of action as preclinical 
work has found that an infusion of a BDNF neutralising antibody 
into the mPFC abolishes ketamine’s antidepressant-like effects 
(Lepack et al., 2014). Additional preclinical work demonstrated 
that (R,S)-ketamine-induced antidepressant effects are associated 
with upregulation of BDNF and mTORC in the hippocampus and 
prefrontal cortex, mediated by AMPA receptors (Zhou et al., 2014).
Considering the individual enantiomers, in a chronic social 
defeat stress and learned helplessness models of depression, a 
TRkB antagonist was able to block the antidepressant effects of 
both (S)-ketamine (Yang et al., 2018a) and (R)-ketamine (Yang 
et al., 2015). Interestingly, (R)-ketamine induced greater effects 
on reduced dendritic spine density, BDNF-TrkB signalling and 
synaptogenesis in the prefrontal cortex and hippocampus com-
pared with (S)-ketamine and (R)-ketamine showed a greater 
potency and longer-lasting antidepressant effect than (S)-ketamine 
in this model (Yang et al., 2015).
Mammalian target of rapamycin complex and 
extracellular signal-regulated kinase
The mammalian target of rapamycin complex 1 (mTORC1) and 
extracellular signal-regulated kinase (ERK) are key signalling 
molecules in pathways that regulate protein synthesis with roles 
in synaptic development and plasticity (Ignacio et al., 2016; 
Mendoza et al., 2011). The function of mTORC1 and ERK in the 
antidepressant actions of ketamine and its enantiomers are not 
completely clear. Work in rodents initially demonstrated that 
(R,S)-ketamine rapidly activated the mTORC pathway, leading 
to increased synaptic signalling proteins and synaptic spine den-
sity (Li et al., 2010). Furthermore, intracerebroventricular admin-
istration of an mTORC1 inhibitor, rapamycin, has been shown to 
block ketamine-induced synaptogenesis and antidepressant-like 
effects (Li et al., 2010, 2011). Other work has shown that (R,S)-
ketamine administration did not alter levels of phosphorylated 
mTOR in the hippocampi of control or BDNF-knockout mice, 
neither were the antidepressant effects of (R,S)-ketamine blocked 
by intraperitoneally administered rapamycin (Autry et al., 2011). 
However, this study did report reduced phosphorylation of ribo-
somal protein s6 kinase in brain tissues, a pharmacodynamic 
readout of mTORC1 inhibition, following rapamycin administra-
tion. One explanation for the failure of rapamycin to block the 
antidepressant effects of (R,S)-ketamine in the study by Autry 
et al. (2011) is that the peripheral route of administration may not 
have achieved sufficient central nervous system exposure com-
pared to studies where intracortical rapamycin administration 
resulted in adequate mTORC1 inhibition to block (R,S)-
ketamine’s antidepressant effects (Li et al., 2010, 2011).
Further preclinical work demonstrated that the antidepressant 
effects of (S)-ketamine but not (R)-ketamine were blocked by 
mTORC1 inhibition and that (S)-ketamine, but not (R)-ketamine, 
significantly attenuated decreased phosphorylation of mTOR in 
the prefrontal cortex of mice in a chronic social defeat stress 
model (Yang et al., 2018b). This same study showed that pre-
treatment with an ERK inhibitor blocked the antidepressant 
effects of (R)-ketamine but not (S)-ketamine and, furthermore, 
(R)-ketamine but not (S)-ketamine significantly attenuated the 
reduced phosphorylation of ERK in the prefrontal cortex and hip-
pocampi of susceptible mice using the same model (Yang et al., 
2018b). It is interesting to note that the antidepressant effects of 
(S)-norketamine, (S)-ketamine’s predominant metabolite, have 
also been shown to be blocked by the mTORC1 inhibitor rapa-
mycin (Yang et al., 2018a). Taken together this suggests that 
mTORC1 has a role in antidepressant effects of (S)-ketamine but 
less so for (R)-ketamine and that ERK activation could instead 
mediate the antidepressant effects of (R)-ketamine (Figure 3).
In a recent randomised double-blind cross-over study, Abdallah 
et al. (2020) explored whether pre-treatment with rapamycin could 
attenuate the rapid antidepressant effects of (R,S)-ketamine in indi-
viduals with MDD. Surprisingly, rapamycin did not alter the acute 
antidepressant effects of (R,S)-ketamine but instead prolonged the 
antidepressant effects (Abdallah et al., 2020). Two weeks after 
ketamine administration there were significantly higher response 
and remission rates following rapamycin + ketamine compared to 
placebo + ketamine. The authors hypothesised that the failure to 
block ketamine’s effects by rapamycin may have been due to the 
dosage used and peripheral route of administration, mirroring the 
findings from preclinical work that also utilised peripheral rapam-
ycin administration (Autry et al., 2011). A key difference between 
this human work and the preclinical work, however, is follow-up 
time. None of the ketamine + rapamycin animal studies discussed 
could have discovered findings as shown in the study by Abdallah 
et al. (2020) as antidepressant effects were not followed up for long 
enough (Autry et al., 2011; Li et al., 2010, 2011). Abdallah et al. 
(2020) also hypothesised that rapamycin may extend the antide-
pressant effects of ketamine via an mTORC1-dependent anti-
inflammatory mechanism (Thomson et al., 2009), protecting 
newly made synapses from inflammatory processes that cause syn-
aptic elimination and undermine the antidepressant effects of keta-
mine, or by enhancing autophagy (a crucial mTORC1 regulated 
process involved in normal cellular plasticity, which involves 
degrading and recycling toxic or dysfunctional cellular compo-
nents) (Abdallah et al., 2020). Alternatively, it is possible to specu-
late rapamycin may have mTORC1-independent effects that 
contribute to the antidepressant effects of ketamine. For example, 
rapamycin may attenuate an unacknowledged homeostatic mecha-
nism that normally contributes to relapse. A final speculative con-
sideration is whether rapamycin may promote longer-lasting 
antidepressant effects of (R)-ketamine via increased ERK signal-
ling as low concentrations of rapamycin have been shown to 
increase Akt and ERK activation in vitro through an mTORC1-
dependent mechanism (Chen et al., 2010). Although interesting, 
these preliminary findings should be interpreted with caution and 
replication in future studies is needed, before back translation to 
animal studies (Abdallah and Krystal, 2020), alongside work to 
determine any differential effects of rapamycin on each of keta-
mine’s enantiomers.
Glycogen synthase kinase 3
Activation of mTORC1 signalling has been linked to phospho-
rylation (deactivation) of glycogen synthase kinase-3 (GSK-3) 
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and inhibition of GSK-3 has been shown to be necessary for the 
rapid antidepressant-like effects of (R,S)-ketamine in mice 
(Beurel et al., 2011). Furthermore, administration of (R,S)-
ketamine in combination with lithium, a non-selective GSK-3 
inhibitor, resulted in rapid activation of the mTORC1 signalling 
pathway, increased inhibitory phosphorylation of GSK-3, 
increased synaptic spine density and potentiated antidepressant-
like responses in rodents (Liu et al., 2013). Ketamine-induced 
inhibition of GSK-3 has also been linked to AMPA receptor 
upregulation and stabilisation at the cell surface. In a preclinical 
study it was demonstrated that (R,S)-ketamine-induced inhibi-
tion of GSK-3 resulted in reduced phosphorylation of post-syn-
aptic density-95 (which regulates AMPA receptor trafficking), 
diminishing the internalisation of AMPA GluA1 subunits (Beurel 
et al., 2016). This could ultimately allow for augmented signal-
ling through AMPA receptors following ketamine treatment.
In clinical work, testing the GSK-3 inhibition hypothesis, 
lithium continuation therapy showed no benefit over placebo at 
2 weeks following the cessation of four (R,S)-ketamine infusions 
in individuals with TRD (Costi et al., 2019). In patients with 
treatment-resistant bipolar depression, maintained on either ther-
apeutic-dose lithium or valproate before receiving (R,S)-
ketamine versus placebo, a significant improvement in depressive 
symptoms was seen in both mood stabiliser groups, and although 
ketamine’s antidepressant effect size relative to placebo was 
larger for lithium (d=2.27) than valproate (d=0.79), there was no 
significant difference observed between these two agents (Xu 
et al., 2015). Furthermore, neither serum lithium nor valproate 
levels correlated with ketamine’s antidepressant efficacy.
Although some evidence highlights GSK-3 as an important 
regulatory target for ketamine’s antidepressant effects, clinical 
studies have not yet confirmed preclinical findings. Further eval-
uation of the role of GSK-3 in the antidepressant effects of keta-
mine’s individual enantiomers and metabolites is still required.
Translocation of Gs alpha subunit from  
lipid rafts
An increase in intracellular cyclic adenosine monophosphate 
(cAMP) that acts to upregulate neurotrophic factors and increase 
synaptogenesis has been associated with conventional antide-
pressant action (Dwivedi and Pandey, 2008; Gass and Riva, 
2007). Gαs is a subunit of the G protein GS that stimulates the 
generation of cAMP by activating adenylyl cyclase. Localisation 
of Gαs within lipid raft microdomains in the plasma membrane 
acts to regulate cellular signalling, and indeed production of 
cAMP is diminished when Gαs is localised to lipid raft microdo-
mains (Allen et al., 2009). A number of preclinical studies have 
demonstrated increases in cAMP through translocation of Gαs 
from lipid raft domains into non-raft regions, augmenting inter-
action between Gαs and adenylyl cyclase, following administra-
tion of various classes of antidepressants (Czysz et al., 2015; 
Toki et al., 1999; Zhang and Rasenick, 2010).
Wray et al. (2019) have since reported that (R,S)-ketamine 
administration to C6 glioma cells led to immediate translocation 
of Gαs from lipid raft domains to non-raft domains and an 
increase in cAMP, followed by an increase in BDNF expression 
after 24 hours. The (R,S)-ketamine induced increase in cAMP 
was found to persist after knocking out the NMDA receptor indi-
cating an NMDA receptor-independent mechanism. Further, 
administration of the ketamine metabolite (2R,6R)-HNK also 
resulted in redistribution of Gαs from lipid rafts and an increase 
cAMP production. These findings suggest the translocation of 
Gαs from lipid rafts is a reliable hallmark of antidepressant 
action; however, further research is needed to examine to what 
degree this mechanism contributes to the antidepressant effect of 
the individual enantiomers of ketamine.
Monoaminergic systems
Several studies suggest that 5-hydroxytryptamine (5-HT) signal-
ling plays a role in the antidepressant effects of ketamine. 
Preclinical work has demonstrated that the antidepressant-like 
action of (R,S)-ketamine is blocked by pre-treatment with a 
5-HT-depleting agent (Fukumoto et al., 2014, 2016; Gigliucci 
et al., 2013). (R,S)-ketamine has been found to inhibit serotonin 
transporter (SERT) function in vitro (Zhao and Sun, 2008) and a 
positron emission tomography (PET) study in conscious monkeys 
further reported that subanaesthetic (R,S)-ketamine selectively 
enhanced serotonergic transmission by inhibition of SERT activity 
(Yamamoto et al., 2013). Alongside SERT inhibition, increased 
mPFC 5-HT release via AMPA receptor stimulation in the dorsal 
raphe nucleus may be involved in the antidepressant effects of 
(R,S)-ketamine (Chaki and Fukumoto, 2019; Pham et al., 2017). 
Moreover, it has been demonstrated that an mPFC infusion of a 
5-HT1a receptor antagonist blocks the antidepressant-like effects of 
(R,S)-ketamine in mice and attenuates ketamine-induced increases 
in phosphorylation of Akt (Fukumoto et al., 2018). (R,S)-ketamine 
antidepressant effects were mimicked by intra-mPFC, but not sys-
temic, administration of a 5-HT1a receptor agonist and both the 
antidepressant effects of ketamine and the 5-HT1a receptor agonist 
were blocked by the mTORC1 inhibitor rapamycin (Fukumoto 
et al., 2018). Finally, in a recent study, infusion of a selective 
5-HT1A receptor agonist into the mPFC produced ketamine-like 
rapid synaptic and antidepressant-like behavioural responses in a 
rodent model that were blocked by co-infusion of an AMPA recep-
tor antagonist (Fukumoto et al., 2020). Taken together, it appears 
another route via which (R,S)-ketamine may cause its antidepres-
sant effects is through 5-HT1A receptor activation in the mPFC, by 
AMPA receptor-dependent 5-HT release, with downstream con-
vergence on signalling mechanisms. These include the Akt/
mTORC1 pathway but may also include ERK signalling, which is 
also activated by direct 5HT1A receptor stimulation (Buritova 
et al., 2009; Newman-Tancredi et al., 2009).
Considering the individual enantiomers, an in vivo microdialy-
sis study has shown that both (R)- and (S)-ketamine acutely 
increase 5-HT release in the prefrontal cortex, with (R)-ketamine 
causing a greater increase than (S)-ketamine (Ago et al., 2019). 
Although the (S)-ketamine-induced 5-HT release was attenuated 
by an AMPA receptor antagonist, (R)-ketamine-induced 5-HT 
release was not affected by AMPA receptor blockade. Although 
preclinical work has demonstrated that 5-HT depletion abolishes 
the antidepressant-like actions of (S)-ketamine in a genetic model 
of depression (du Jardin et al., 2016), other work has shown that 
5-HT depletion does not alter the antidepressant effects of 
(R)-ketamine in a chronic social defeat stress model (Zhang et al., 
2018). This suggests that 5-HT may not play as major a role in 
antidepressant effects of (R)-ketamine. The reason for these differ-
ences is not entirely clear and further work is needed to explore the 
role of 5-HT in the effects of ketamine and its enantiomers.
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The dopamine system has also been implicated in depression 
and the antidepressant effects of ketamine; however, the mecha-
nism underlying the action of ketamine or its enantiomers on this 
system has not been fully established. Acute subanaesthetic (R,S)-
ketamine administration is associated with significantly increased 
dopamine levels in the cortex, striatum and nucleus accumbens in 
rodents (Kokkinou et al., 2018) and there is also in vivo PET 
imaging evidence that (R,S)-ketamine and (S)-ketamine adminis-
tration leads to increased striatal dopamine release in humans as 
indexed by D2/D3 receptor tracer binding (Breier et al., 1998; 
Smith et al., 1998; Vollenweider et al., 2000). A further PET study 
found that IV (S)-ketamine administration, but not (R)-ketamine, 
led to a significant reduction of binding availability of dopamine 
D2/D3 receptor in the monkey striatum and suggests that unlike 
(R)-ketamine, (S)-ketamine can cause dopamine release in the 
striatum that may contribute to the psychotomimetic/dissociative 
side effects in humans (Hashimoto et al., 2017). Other groups 
found that (R,S)-ketamine-induced reductions of D2/D3 binding in 
humans only occurred in combination with amphetamine, sug-
gesting ketamine may enhance the sensitivity of the dopamine 
system but not lead to direct dopamine release (Aalto et al., 2002, 
2005; Kegeles et al., 2002).
In a study examining the effects of (R,S)-ketamine and 
metabolites on evoked striatal dopamine release and dopamine 
receptors, (R,S)-ketamine did not alter the magnitude or kinetics 
of electrical stimulation-evoked dopamine release in the nucleus 
accumbens of anesthetised mice and neither ketamine’s enanti-
omers nor its metabolites had affinity for dopamine receptors or 
the dopamine transporter (Can et al., 2016). This suggests the 
side effects and antidepressant actions of ketamine (or its metab-
olites) may not be associated with direct effects on mesolimbic 
dopaminergic neurotransmission. An alternative hypothesis is 
that ketamine produces indirect effects through NMDA receptor 
antagonism on GABAergic interneurons, resulting in disinhibi-
tion of glutamatergic projections on to dopamine neurons in the 
midbrain, an increase in glutamate release, subsequent activation 
of dopaminergic neurons and increased dopamine levels in tar-
gets such as the striatum and cortex (Stone et al., 2007).
Additional research findings indicate that dopamine D1 recep-
tor activity in the mPFC are necessary for the rapid antidepressant 
actions of (R,S)-ketamine using optogenetic stimulation in a 
mouse model (Hare et al., 2019). Another potential convergence 
from a signal transduction perspective may involve NMDA and D1 
receptor-dependent induction of mTORC/ERK and inactivation of 
eEF2 kinase resulting in increased protein synthesis (David et al., 
2020). Further work found that pre-treatment with a dopamine D1 
receptor antagonist did not block the antidepressant effects of 
(R)-ketamine in a chronic social defeat stress model (Chang et al., 
2020). Furthermore, although (S)-ketamine has been shown to 
cause a robust increase in dopamine release compared with 
(R)-ketamine, the antidepressant-like effects were more potent and 
longer acting following (R)-ketamine administration in a mouse 
model (Ago et al., 2019). Taken together, these findings suggest 
that activation of the dopamine system may be required for the 
antidepressant actions of (S)- but not (R)-ketamine.
Inhibition of lateral habenula bursting
Increasing lines of preclinical and clinical evidence highlight a 
major role for the lateral habenula, an anti-reward centre, in the 
pathophysiology of depression. It is suggested that abnormal 
increases in neuronal activity in this region signal downregula-
tion of brainstem dopaminergic and serotonergic firing, result-
ing in depressive symptomatology including anhedonia, 
helplessness and excessive focus on negative experiences (Gold 
and Kadriu, 2019).
Recent work from Yang et al. (2018c) found that blockade of 
NMDA receptor-dependent bursting activity in the lateral habenula 
mediated the antidepressant actions of (R,S)-ketamine in rodent 
models of depression. It was demonstrated that lateral habenula 
bursting required both NMDA receptors and low-voltage-sensitive 
T-type calcium channels. Furthermore, administration of T-type 
calcium channel inhibitors (ethosuximide and mibefradil) caused 
rapid antidepressant-like effects in both the forced swim test and 
sucrose preference test (Yang et al., 2018c). In contrast, preclinical 
work utilising a chronic social defeat stress model failed to demon-
strate antidepressant effects of ethosuximide whereas (R)-ketamine 
showed rapid and long-lasting antidepressant actions in this model 
(Tian et al., 2018). Furthermore, a recent double-blind RCT in 
medication-free patients with depression found no significant 
reductions in depression and anxiety scores following treatment 
with ethosuximide, suggesting T-type calcium channel inhibitors 
are unlikely to exert ketamine-like robust antidepressant actions 
(Zhang et al., 2020a).
It should be noted that inhibition of lateral habenula bursting 
as a mechanism of antidepressant action has only been assessed 
acutely at 1 hour post (R,S)-ketamine infusion (Yang et al., 
2018c). Whether this mechanism is active later during (R,S)-
ketamine’s antidepressant effects (>24 hours) or indeed if there 
are differential effects of (S)- and (R)-ketamine on lateral 
habenula bursting remains unknown.
Opioid receptor system
Ketamine interacts with mu, kappa and, to a lesser extent, delta-
opioid receptors (Ki = 42.1, 28.1, and 272 mΜ, respectively) 
(Hirota et al., 1999; Zanos et al., 2018). The affinity of 
(S)-ketamine for the mu and kappa opioid receptors is two to 
fourfold that of (R)-ketamine (Hirota et al., 1999; Hustveit et al., 
1995). Recent work demonstrated that pre-treatment with nal-
trexone, an opioid receptor antagonist, significantly blocked the 
antidepressant and anti-suicidal effects of (R,S)-ketamine in 
TRD, suggesting that opioid system activation was necessary for 
the rapid-acting antidepressant and antisuicidal effects of (R,S)-
ketamine (Williams et al., 2018, 2019). There are a number of 
important limitations to these studies including the small sample 
size (only 12 participants completing both naltrexone and pla-
cebo pre-treatment conditions and only seven of the 12 meeting 
response criteria during the ketamine plus placebo condition), 
lack of a placebo control arm for the (R,S)-ketamine infusion 
(i.e., naltrexone + IV saline and placebo + IV saline) and finally 
that participants may have experienced a noxious, nocebo type of 
response to the naltrexone + ketamine treatment, which influ-
enced subsequent depression ratings (Mathew and Rivas-
Grajales, 2019). Other work has demonstrated that naltrexone 
pre-treatment did not affect the antidepressant effects of (R,S)-
ketamine in depressed individuals with alcohol use disorder 
(Yoon et al., 2019) and an earlier study in healthy individuals 
found that the behavioural effects of an antidepressant dose of 
ketamine were potentiated by pre-treatment with naltrexone 
116 Journal of Psychopharmacology 35(2)
(Krystal et al., 2006). Finally, in patients with TRD, concurrent 
use of buprenorphine and methadone (high affinity mu opioid 
receptor agonists) was not associated with reductions in antide-
pressant efficacy of (R,S)-ketamine (Marton et al., 2019).
In rodent models of depression (chronic social defeat stress and 
inflammation induced), it was shown that naltrexone pre-treatment 
did not block the antidepressant effects of (R,S)-ketamine (Zhang 
and Hashimoto, 2019). However, in a subsequent preclinical study, 
it was shown that opioid antagonists abolish the ability of (R,S)-
ketamine to reduce depression-like behavioural and lateral 
habenula cellular hyperactivity (Klein et al., 2020). The authors 
suggested the opioid system is ‘necessary but not sufficient’ for the 
antidepressant actions of (R,S)-ketamine in rodents as activation 
by morphine, a mu-opioid agonist, at a dose high enough to induce 
a hedonic response, did not mimic the rapid antidepressant-like 
effects of ketamine or reduce lateral habenula neuronal activity 
(Klein et al., 2020). The authors argued that in their studies of lat-
eral habenula cellular activity, (R,S)-ketamine did not appear to act 
as a mu-opioid agonist but that some mu-opioid receptor activity 
was necessary for NMDA receptor antagonism. In brain regions, 
including the habenula, NMDA receptors and opioid receptors dis-
play colocalisation (Rodriguez-Munoz et al., 2012) and NMDA 
receptor activation can be modulated by actions of opioid receptors 
(Kow et al., 2002; Martin et al., 1997). Taken together, this sug-
gests a potential interaction that may be explained by direct ‘cross-
talk’ between the glutamatergic and the opioid receptor systems 
(Chartoff and Connery, 2014), or by convergence at downstream 
signalling pathways.
Figure 3. Proposed signalling pathways underlying the antidepressant actions of ketamine enantiomers and metabolites. Top: (S)-ketamine causes 
glutamate release via disinhibition of γ-aminobutyric acid (GABA) interneurons. Resulting glutamate surge stimulates α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors leading to release of brain-derived neurotrophic factor (BDNF) with resulting activation of tropomyosin 
kinase B (TrkB)-Akt-mammalian target of rapamycin complex 1 (mTORC1) signalling. This leads to increased synthesis of proteins required for 
synaptogenesis. (S)-ketamine and (S)-norketamine suppress resting N-Methyl-D-Aspartate (NMDA) receptor activity, deactivating eukaryotic 
elongation factor 2 (eEF2) kinase, resulting in reduced eEF2 phosphorylation, augmentation of BDNF synthesis and TrkB-mTORC1 activation. Bottom: 
(R)-ketamine causes glutamate release via disinhibition of GABA interneurons with activation of AMPA receptors and BDNF release but there may 
be an alternative pathway by which (R)-ketamine stimulates AMPA receptor transmission that still needs to be elucidated. (R)-ketamine may cause 
preferential activation of TrkB-MEK-ERK signalling pathway leading to synaptogenesis. (2R,6R)-HNK directly activates AMPA receptors and inhibition 
of group II metabotropic glutamate (mGlu2) receptors may also be involved in this metabolite’s antidepressant actions.
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There are several potential convergences between opioid sig-
nalling and other mechanisms implicated in the antidepressant 
action of ketamine. For example, administration of endogenous 
opioids has been shown to upregulate BDNF expression in the 
frontal cortex, hippocampus and amygdala (Zhang et al., 2006). 
Moreover, these effects were reversed by naltrexone administra-
tion. Acute mu-opioid receptor activation has been shown to result 
in rapid activation of ERK signalling (Bian et al., 2015; Zheng 
et al., 2008) and acute treatment with ketamine enhances the levels 
of opioid-induced ERK phosphorylation in cells that endogenously 
express mu-opioid receptors (Gupta et al., 2011). Further, adminis-
tration of an opioid receptor antagonist, naloxone, has been shown 
to inhibit mu-opioid-induced ERK activation in a dose-dependent 
manner in C6 glioma cell lines (Gutstein et al., 1997). Finally, 
there are a number of functional interactions between opioid recep-
tors and monoaminergic systems relevant to mood control (Lutz 
and Kieffer, 2013). Specifically, activation of mu-opioid receptors 
expressed in the dorsal raphe nucleus and ventral tegmental area, 
via GABAergic interneurons, disinhibit 5-HT (Fadda et al., 2005; 
Tao and Auerbach, 2002) and dopamine neurons (Le Merrer et al., 
2009) with projections including the prefrontal cortex and nucleus 
accumbens (Lutz and Kieffer, 2013) (Figure 4).
The role of the opioid system in the antidepressant effect of 
ketamine remains controversial and a topic of debate (Amiaz, 2019; 
Heifets et al., 2019; Krystal et al., 2019b; Sanacora, 2019). Further 
work with rigorous trial design and parallel mechanistic studies are 
required to understand the function of the ketamine-opioid receptor 
interaction and subsequent signalling cascades in the antidepressant 
effect of each of ketamine and its individual enantiomers.
Conclusion
The discovery of the rapid antidepressant effects of (R,S)-
ketamine, including in treatment-resistant patients, has appro-
priately been hailed ‘the most important discovery in half a 
century’ in depression research (Duman and Aghajanian, 2012). 
Through the drug development and clinical trials process, the 
(S)-ketamine nasal spray, SpravatoTM, has been approved in 
both the United States and Europe, although some concerns 
remain regarding efficacy and side effects. The first pilot study 
of (R)-ketamine in TRD has demonstrated encouraging results 
and, considering preclinical findings, it appears (R)-ketamine 
may have a more favourable safety profile than (S)-ketamine. 
Accumulating preclinical evidence also suggests (R)-ketamine 
to have more potent and longer-lasting antidepressant effects 
than both (R,S)-ketamine and (S)-ketamine. As studies of 
(R)-ketamine progress through Phase I and Phase II, results 
from direct comparison studies of the safety and efficacy of 
(R)-ketamine and (S)-ketamine in TRD will be crucial. Other 
key outstanding questions are outlined in Figure 5.
Figure 4. Hypothesised monoamine and opioid mechanisms and potential convergences with signalling pathways implicated in the antidepressant 
actions of ketamine. (a) (R,S)-ketamine inhibits lateral habenula (LHb) bursting via actions on N-Methyl-D-Aspartate (NMDA)/low voltage sensitive 
t-type channels (T-VSCC)/mu-opioid receptors (MOR). This results in disinhibition of monoamine release via γ-aminobutyric acid (GABA)-ergic 
interneurons in the dorsal raphe nucleus (DRN) and ventral tegmental area (VTA) to projections including the medial prefrontal cortex (mPFC) and 
nucleus accumbens (NAcc). Action of (R,S)-ketamine on NMDA/MOR on GABAergic interneurons in the DRN and VTA may be a further mechanism of 
disinhibition of 5-HT and dopamine release. 5-HT release in mPFC may also occur via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor stimulation in DRN for (R,S)-ketamine and (S)-ketamine but might not be as relevant for (R)-ketamine. (b) Stimulation of postsynaptic 
5-HT1A receptors via 5-HT in mPFC results in activation of Akt/mammalian target of rapamycin complex 1 (mTORC1) and potentially ERK signalling. 
Stimulation of postsynaptic D1 receptor via dopamine may result in activation of mTORC1/ERK and inactivation of eukaryotic elongation factor 2 
(eEF2) kinase. Postsynaptic MOR activation may also potentiate the ERK signalling pathway.
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Although NMDA receptor inhibition and subsequent AMPA 
receptor activation have a role in the antidepressant effects of keta-
mine, further mechanistic work is building a more nuanced under-
standing of the distinct molecular and cellular mechanisms of 
ketamine, its enantiomers and metabolites, including BDNF-TrkB, 
mTORC1 and ERK signalling. Although there may be a role for 
monoaminergic and opioid receptor systems in the antidepressant 
effects or detrimental side effects of ketamine, further work exam-
ining the effects of each of the component enantiomers on these 
systems is required. All the while, new pieces of the ketamine puz-
zle are being discovered and other potential future directions of 
enquiry include examining the role of the transforming growth fac-
tor β1 system (Zhang et al., 2020b) and the brain-gut-microbiome 
axis (Huang et al., 2019; Yang et al., 2017b) in the antidepressant 
effects of ketamine and its enantiomers.
As we further our understanding of the similarities and differ-
ences in the signalling pathways associated with (S)-ketamine, 
(R)-ketamine and their metabolites, we should bear in mind 
potential complementary or synergistic antidepressant effects 
that might arise via distinct mechanisms. A deeper understanding 
of the precise molecular and cellular mechanisms underlying the 
antidepressant effects and negative side effects of (R,S)-ketamine, 
(S)-ketamine and (R)-ketamine will be invaluable as we seek to 
develop future rapid-acting antidepressants with favourable 
safety profiles, alongside treatment strategies to maintain ade-
quate response.
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- What are the neural targets for (R)-ketamine and (2R,6R)-hydroxynorketamine (HNK)?
  A fundamental issue that is limiting further understanding of the antidepressant properties of (R)-ketamine and (2R,6R)-HNK is that the 
initial target(s) responsible for their behavioural and synaptic effects are still unclear. Challenging the N-Methyl-D-Aspartate (NMDA) 
receptor inhibition hypothesis, although (R)-ketamine has approximately three to four-fold lower affinity for blocking the NMDA recep-
tor compared to (S)-ketamine, preclinical work has demonstrated it to have more potent antidepressant-like effects than (S)-ketamine 
(Yang et al., 2015, 2017a; Zanos et al., 2016; Zhang et al., 2014). Similarly, (2R,6R)-HNK, at lower concentrations than would inhibit 
the NMDA receptor, has been demonstrated to have rapid and persistent antidepressant-like effects (Zanos et al., 2016). Taken together, 
this suggests alternative molecular targets that exert rapid antidepressant effects independent of NMDA receptor inhibition. For ex-
ample, (R)-ketamine and (2R,6R)-HNK appear to stimulate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) recep-
tor, either directly or downstream; however, the pathway by which (R)-ketamine stimulates AMPA receptor transmission independent of 
NMDA blockade still needs to be elucidated (Chaki, 2017). Until there is a clearer understanding of target engagement, it is difficult to 
interpret dose-related effects of (2R,6R)-HNK and (R)-ketamine. In clinical studies, (2R,6R)-HNK levels are a poor predictor of antide-
pressant response (Farmer et al., 2020; Grunebaum et al., 2019; Zarate et al., 2012a). Is that because (2R,6R)-HNK levels are too low to 
produce clinical benefit? Is that because (2R,6R)-HNK is not an effective antidepressant in humans? Understanding target engagement 
will be a key step in addressing these questions. 
- Is (R)-ketamine an independently effective antidepressant? 
  Although (R)-ketamine appears to be a more effective antidepressant in preclinical models (Yang et al., 2015, 2017a; Zanos et al., 2016; 
Zhang et al., 2014), the antidepressant efficacy of (S)-ketamine is currently the best validated of all the candidate drugs ((R,S)-ketamine, 
(S)-ketamine, (R)-ketamine, (2R,6R)-HNK, (S)-norketamine) (Canuso et al., 2018; Daly et al., 2018, 2019; Popova et al., 2019). If 
(R)-ketamine proves to be an independently effective antidepressant in clinical studies (the initial open-label pilot study is insufficient 
to make this case (Leal et al., 2020)) then the conclusion would be that both (S)-ketamine and (R)-ketamine contribute to the antidepres-
sant effects of (R,S)-ketamine. It is important to remember that the efficacy of one enantiomer does not negate the potential efficacy 
of the other. Indeed, if (S)-ketamine and (R)-ketamine differ in their mechanisms of action it is possible they have complementary or 
synergistic antidepressant effects (Krystal et al., 2019a). This is similarly true for their metabolites (S)-norketamine and (2R,6R)-HNK.
- What is the optimal antidepressant dose of (R)-ketamine?
  Considering that (S)-ketamine has three to four-fold higher affinity for the NMDA receptor, if (R)-ketamine was found to have antide-
pressant efficacy at a dose that was equal to or lower than (S)-ketamine’s minimum therapeutic dose, this would support an alternative 
target to the NMDA receptor. However, if (R)-ketamine demonstrated more rapid or robust efficacy at three to four times this dose, it 
would once again implicate NMDA receptor inhibition as a major target. 
Figure 5. Outstanding questions.
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